This move is archived. Current quotes and coverage live on the stock page.
Follow VRTX
Vertex Pharmaceuticals is seeing a notable rise in its stock price, thanks to positive market sentiment and expectations for upcoming earnings.
Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) are up today by 2.86%, closing at CA$525.35. This increase comes as investors respond to recent trends and upcoming earnings reports that indicate potential growth.
Vertex Pharmaceuticals Inc
VRTX.US
VRTX.US
Vertex Pharmaceuticals Inc
WealthAwesomeMarket cap
$141.65B
P/E
32.5x
52W high
$568.67
52W low
$406.67
1W change
+6.89%
Beta
0.28
Analyst Price Targets
Based on 32 analysts covering VRTX · as of Nov 2, 2026
Wall Street analysts forecast VRTX stock price to rise 3.3% over the next 12 months.
Consensus
Buy4.34 / 5.00
Avg. Target
C$571.46
+3.3% Upside
Current Price
C$553.15
Last close
Analyst Breakdown (32 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on VRTX's historical volatility
30-Day Vol
27.6%
Annualized
90-Day Vol
28.9%
Annualized
Trend (90d)
+45.7%
Annualized drift
90d Mean
C$651.32
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$584.11 | C$531.00 – C$642.53 |
| 60 trading days | C$616.80 | C$539.00 – C$705.82 |
| 90 trading days | C$651.32 | C$552.18 – C$768.25 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors are optimistic about Vertex's strong revenue growth forecasts and the company's solid performance in the biotechnology sector, even with some recent volatility.
2.86% Increase in Vertex's Stock Price
Vertex Pharmaceuticals' stock has increased by 2.86%, reflecting investor confidence in the company's growth potential and upcoming earnings performance.
Bull case
Vertex is expected to deliver strong earnings and revenue growth, with a consensus estimate of $4.84 per share for the current quarter, showing a year-over-year increase. The company is also projected to reach a revenue of $3.4 billion, which is a 10.4% growth from last year.
Bear case
Despite the positive outlook, Vertex's stock has experienced fluctuations, with a -6.7% return in recent months. Analysts have pointed out a slight decline in earnings estimate revisions, which might dampen investor enthusiasm.
Strong Earnings Expectations
Vertex Pharmaceuticals is expected to report earnings of $4.84 per share for the current quarter, a slight increase from last year. This positive outlook is backed by a revenue forecast of $3.4 billion, representing a 10.4% year-over-year growth. Investors are closely watching these developments as they could significantly impact the stock's performance in the near term.
Market Sentiment and Stock Performance
The recent rise in Vertex's stock price aligns with a broader positive sentiment in the biotechnology sector. Even though it faced a -6.7% return over the past month, the current uptick indicates renewed investor interest. Analysts are keeping an eye on earnings estimate revisions, which often correlate with short-term stock price movements, as they can provide insights into the company's future performance.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
